Publications in collaboration with researchers from University Hospital Brno (11)

2024

  1. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

    Haematologica, Vol. 109, Núm. 3, pp. 867-876

2021

  1. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798

  2. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718

  3. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    Journal of Hematology and Oncology

  4. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    European Journal of Haematology, Vol. 104, Núm. 5, pp. 435-442

  2. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: Subgroup analysis of the phase 3 CASTOR and POLLUX studies

    Haematologica, Vol. 105, Núm. 2, pp. 468-477

  3. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 395, Núm. 10218, pp. 132-141

  4. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

    Leukemia, Vol. 34, Núm. 2, pp. 589-603

2018

  1. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

    New England Journal of Medicine, Vol. 378, Núm. 6, pp. 518-528

2017

  1. Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

    Haematologica, Vol. 102, Núm. 10, pp. 1767-1775